Anti-Human CD44 (Clone E1/2) – DyLight® 550

Anti-Human CD44 (Clone E1/2) – DyLight® 550

Product No.: C1797

[product_table name="All Top" skus="C1797"]

- -
- -
Clone
E1/2
Target
CD44
Formats AvailableView All
Product Type
Monoclonal Antibody
Alternate Names
Hermes, Pgp-1, H-CAM, HUTCH-1, ECMR III, gp85, Ly-24
Isotype
IgG1
Applications
FC

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Human
Host Species
Mouse
Product Concentration
0.2 mg/ml
Formulation
This DyLight® 550 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Storage and Handling
This DyLight® 550 conjugate is stable when stored at 2-8°C. Do not freeze.
Country of Origin
USA
Shipping
Next Day 2-8°C
Excitation Laser
Yellow Laser (563 nm)
Applications and Recommended Usage?
Quality Tested by Leinco
FC The suggested concentration for this E1/2 antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl or 100μl of whole blood. Titration of the reagent is recommended for optimal performance for each application.
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Description

Specificity
Clone E1/2 recognizes human CD44.
Background
CD44 is an 80-95 kD glycoprotein that plays a role in various cellular functions including lymphocyte activation, recirculation and homing, hematopoiesis, and tumor metastasis. CD44 interacts with osteopontin, collagens, and matrix metalloproteinases (MMPs) and is a receptor for hyaluronic acid. Transcripts for this gene go through intricate alternative splicing that result in a variety of functionally distinct isoforms, including those which may be related to tumor metastasis. These splice variants of CD44 function as receptors under hemodynamic flow conditions that are significant to the development of cancer metastasis. Hence, it is thought that anti-CD44 tumor-specific mAbs may have therapeutic potential. This therapeutic potential of anti-CD44 mAbs is evident in some animal experiments demonstrating a reduction in malignant activities of various neoplasms when CD44 was targeted by a combination of mAbs, antisense oligonucleotides, and CD44-soluble proteins. It has been reported that high levels of CD44 on leukemic cells fuel leukemia production. Notably, various cancer studies show conflicting results pertaining to level of CD44 expression and its correlation with disease prognosis. Before anti-CD44 therapy can be applied to human cancers, it is essential to resolve this inconsistency.
Antigen Distribution
CD44 is expressed on all leukocytes, endothelial cells, hepatocytes, and mesenchymal cells in addition to B-cells, monocytes, macrophages and certain subsets of thymocytes and peripheral T-cells. Mice with the Ly-24.1 allotype have high densities of CD44+ T-cells.
Ligand/Receptor
Hyaluronan, MIP-1β, fibronectin, collagen
PubMed
NCBI Gene Bank ID
Research Area
Cell Adhesion
.
Cell Biology
.
Immunology
.
Stem Cell

References & Citations

1. Isacke, M.C. et al. (1986) Immunogenetics 23:326
Flow Cytometry

Certificate of Analysis

Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.